23 results
424B5
MLTX
MoonLake Immunotherapeutics - Ordinary Shares
29 Jun 23
Prospectus supplement for primary offering
4:02pm
research, principal investment, hedging, financing and brokerage activities. Some of the underwriters and certain of their affiliates may in the future
424B5
MLTX
MoonLake Immunotherapeutics - Ordinary Shares
26 Jun 23
Prospectus supplement for primary offering
4:23pm
research, principal investment, hedging, financing and brokerage activities. Some of the underwriters and certain of their affiliates may
POS AM
MLTX
MoonLake Immunotherapeutics - Ordinary Shares
1 May 23
Prospectus update (post-effective amendment)
4:05pm
or in privately negotiated transactions;
through the writing or settlement of options or other hedging transactions, whether through an options exchange … this prospectus.
In connection with the sale of the Registrable Shares, the Selling Shareholders may enter into hedging transactions with broker-dealers or other
DEF 14A
MLTX
MoonLake Immunotherapeutics - Ordinary Shares
26 Apr 23
Definitive proxy
4:31pm
of the amendment or waiver. Our Board is responsible for applying and interpreting the code in situations where questions are presented to it.
Anti-Hedging Policy … ; and (d) hedging transactions.
Compensation Committee Interlocks
None of the members of our Compensation Committee has at any time during the prior
8-K
EX-10.7
9okkr0d4e3 u694o
11 Apr 22
Entry into a Material Definitive Agreement
4:40pm
8-K
EX-3.1
54c4wpnn3 1iuzgq9n
11 Apr 22
Entry into a Material Definitive Agreement
4:40pm
DEFA14A
EX-10.3
fjde2wc 1h029pbghtex
4 Oct 21
Additional proxy soliciting materials
7:13am
8-K
EX-10.3
075rbq04lfh5b
4 Oct 21
Entry into a Material Definitive Agreement
7:07am
8-K
EX-3.1
brb566yn80xm
22 Oct 20
Helix Acquisition Corp. Announces Pricing of $100 Million Initial Public Offering
5:06pm
424B4
qyfe7 sq5
21 Oct 20
Prospectus supplement with pricing info
5:06pm